Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568184 | 0.79 | TGM2 (0.61) | LRRK2MEN1KMT2ARPS6KA3 | |
| SCHEMBL11546561 | 0.79 | TGM2 (0.61) | LRRK2MAOAMAOBKDRRPS6KA3 | |
| 5-Fluoroisatin SCHEMBL183575 | 0.76 | MAOB (0.61) | LRRK2CA1CA2MAOAMAOB | |
| SCHEMBL11632681 | 0.76 | ALDH1A1 (0.64) | LRRK2FLT3CDK2CCNE1MAOA | |
| SCHEMBL29548142 | 0.74 | LRRK2 (0.55) | LRRK2MEN1KMT2AMAOAMAOB | |
| 5-Fluoroisatin SCHEMBL28512324 | 0.74 | MAOB (0.59) | LRRK2CA1CA2MAOAMAOB | |
| SCHEMBL10627555 | 0.74 | LRRK2 (0.55) | LRRK2MEN1KMT2AMAOAMAOB | |
| SCHEMBL15145700 | 0.73 | LRRK2 (0.49) | LRRK2FLT3MEN1KMT2ACA1 | |
| 5-Fluoroisatin SCHEMBL29155951 | 0.73 | MAOB (0.58) | LRRK2CA1CA2MAOAMAOB | |
| SCHEMBL12327593 | 0.73 | FLT3 (0.50) | LRRK2FLT3MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130346-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3609896-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018188047-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| EP-2509946-B1 | SPIRO INDOLE-CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8354443-B2 | Cyclopropane indolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2509946-A1 | SPIRO INDOLE - CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| WO-2011069298-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070039-A1 | SPIRO INDOLE - CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-4179561-A | REACTING A 3-DIAZOOXINDOLE WITH A SUBSTITUTED ACETYLENE | E. R. SQUIBB & SONS, INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4112096-A | ANTIALLERGENS | E. R. SQUIBB & SONS, INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4076818-A | ANTIALLERGENS | E. R. SQUIBB & SONS, INC. (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | LRRK2 478/4885FLT3 4115/4885MEN1 2653/4885 |
| US-20210130346-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | LRRK2 1524/4885FLT3 1454/4885MEN1 730/4885 |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | LRRK2 500/4885FLT3 4159/4885MEN1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.